- Home
- ROIV vs HOLX Comparison
ROIV vs HOLX Comparison
Compare ROIV & HOLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ROIV | HOLX |
|---|---|---|
| Founded | 2014 | 1985 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Electronics |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.1B | 16.6B |
| IPO Year | N/A | 1990 |
Fundamental Metrics
Financial Performance| Metric | ROIV | HOLX |
|---|---|---|
| Price | $21.70 | $75.16 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 8 | 15 |
| Target Price | $21.94 | ★ $79.64 |
| AVG Volume (30 Days) | ★ 6.7M | 2.9M |
| Earning Date | 11-10-2025 | 02-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.49 |
| Revenue | $20,329,000.00 | ★ $4,100,500,000.00 |
| Revenue This Year | N/A | $6.69 |
| Revenue Next Year | $376.94 | $5.74 |
| P/E Ratio | ★ N/A | $30.12 |
| Revenue Growth | N/A | ★ 1.74 |
| 52 Week Low | $8.73 | $51.90 |
| 52 Week High | $22.45 | $76.29 |
Technical Indicators
Market Signals| Indicator | ROIV | HOLX |
|---|---|---|
| Relative Strength Index (RSI) | 62.44 | 70.32 |
| Support Level | $20.14 | $74.77 |
| Resistance Level | $21.48 | $75.05 |
| Average True Range (ATR) | 0.71 | 0.28 |
| MACD | 0.00 | -0.12 |
| Stochastic Oscillator | 65.96 | 77.85 |
Price Performance
Historical ComparisonAbout ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
About HOLX Hologic Inc.
Hologic manufactures proprietary products for the healthcare needs of women. The company operates in four segments: diagnostics (44% of total sales), breast health (38%), surgical (16%), and skeletal health (2%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (69%), followed by Europe (20%), Asia (8%), and other international markets (3%). Hologic is headquartered in Bedford, Massachusetts.